These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20597665)

  • 21. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
    Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
    Clin Infect Dis; 2024 Jul; 79(1):60-69. PubMed ID: 38527855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
    Weiss E; Zahar JR; Alder J; Asehnoune K; Bassetti M; Bonten MJM; Chastre J; De Waele J; Dimopoulos G; Eggimann P; Engelhardt M; Ewig S; Kollef M; Lipman J; Luna C; Martin-Loeches I; Pagani L; Palmer LB; Papazian L; Poulakou G; Prokocimer P; Rello J; Rex JH; Shorr AF; Talbot GH; Thamlikitkul V; Torres A; Wunderink RG; Timsit JF
    Clin Infect Dis; 2019 Nov; 69(11):1912-1918. PubMed ID: 30722013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.
    Housman ST; Kuti JL; Nicolau DP
    Clin Chest Med; 2011 Sep; 32(3):439-50. PubMed ID: 21867814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
    Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
    Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
    Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Talbot GH; Das A; Cush S; Dane A; Wible M; Echols R; Torres A; Cammarata S; Rex JH; Powers JH; Fleming T; Loutit J; Hoffmann S;
    J Infect Dis; 2019 Apr; 219(10):1536-1544. PubMed ID: 30649434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
    Ericson JE; McGuire J; Michaels MG; Schwarz A; Frenck R; Deville JG; Agarwal S; Bressler AM; Gao J; Spears T; Benjamin DK; Smith PB; Bradley JS;
    Pediatr Infect Dis J; 2020 Aug; 39(8):658-664. PubMed ID: 32150005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the prevalence of pathogens causing hospital-acquired bacterial pneumonia and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity-score-matched study.
    Choi MH; Kim D; Lee KH; Cho JH; Jeong SH
    Int J Antimicrob Agents; 2023 Sep; 62(3):106886. PubMed ID: 37343808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scenario 1: a patient with hospital-acquired bacterial pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S10-1. PubMed ID: 20597655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options for nosocomial pneumonia due to MRSA.
    Niederman MS
    J Infect; 2009 Sep; 59 Suppl 1():S25-31. PubMed ID: 19766886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries.
    Lagamayo EN
    Am J Infect Control; 2008 May; 36(4 Suppl):S101-8. PubMed ID: 18468549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of ventilator-associated pneumonia.
    Diaz E; Ulldemolins M; Lisboa T; Rello J
    Infect Dis Clin North Am; 2009 Sep; 23(3):521-33. PubMed ID: 19665081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of gram-negative bacteria in healthcare-associated pneumonia.
    Restrepo MI; Anzueto A
    Semin Respir Crit Care Med; 2009 Feb; 30(1):61-6. PubMed ID: 19199188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
    Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems.
    Kollef MH
    Respir Care; 2004 Dec; 49(12):1530-41. PubMed ID: 15571647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial treatment of hospital-acquired pneumonia.
    Fagon JY; Chastre J
    Clin Chest Med; 2005 Mar; 26(1):97-104. PubMed ID: 15802171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bartlett JG; Barie PS; Niederman MS; Wunderink RG
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654
    [No Abstract]   [Full Text] [Related]  

  • 39. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia?
    Niederman MS; Soulountsi V
    Clin Chest Med; 2011 Sep; 32(3):517-34. PubMed ID: 21867820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
    Tillotson GS; Echols RM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.